Accro Bioscience
Innovative drugs for inflammation and autoimmune disease
Accro Bioscience was founded in 2017, is headquartered in Suzhou, China, lists 11–50 employees, and has $100.0M in recorded funding across 2 rounds.
- Headquarters
- Suzhou
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- accropeutics.com
- Total Funding
- $100.0M
- Last Round
- $50.0M Series CMay 2026
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 9 investors for this company. The full record is or through the API.
About
Accropeutics (Accro Bioscience) is a Suzhou, China-based clinical-stage biotech focused on inflammation, autoimmune diseases, and cancer. Its lead asset AC-101, a RIPK2 inhibitor, received FDA IND clearance for Phase II in moderate-to-severe ulcerative colitis. A secondary asset AC-201 targets TYK2/JAK1 for non-infectious uveitis. The company secured $12M in Series B Plus financing in March 2025.
Summary
Accro Bioscience is a Biotech company based in Suzhou, China, founded in 2017. It lists 11–50 employees. It has raised $100.0M in total across 2 rounds, most recently a $50.0M Series C round in May 2026. Investors include OrbiMed, Hongtai Capital Holdings and Shenzhen Capital Group.
Funding History
May 2026
Sign up to see all 2 events
Funding: Series B through Series C. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/accro-bioscience"><img src="https://indexed.vc/api/badge/company/accro-bioscience" alt="Accro Bioscience on Indexed.vc" width="260" height="76" /></a>